Is CSL the best blue-chip share on the S&P/ ASX200?

An Australian share market success story.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite the CSL Limited (ASX: CSL) share price being down 17% from its all-time highs, it still remains one of Australia's greatest ASX success stories.

Headquartered in Melbourne, CSL has become a global biotech company by focussing on "saving lives and protecting the health of people who were stricken with a range of serious and chronic medical conditions". This focus has led the company's share price to grow at an annualised rate of 19.3% over the last decade, excluding its growing dividend.

The company has a number of products on the market, however its core product is its blood plasma collection business. Analysts believe that this business can grow by high single digits for the foreseeable future. Because of this robust growth the company is aiming to open between 30 to 35 new collection centres this financial year.

CSL currently has five new products moving into human clinical trials. The company has a strong history of investing in research and development (R&D), in order to generate a diverse and growing revenue base. At 31 December 2018, CSL spent 8.7% of total operating revenue on R&D.

A financial key

One of the keys to CSL's share price success is the exceptional 42% return-on-equity (RoE) that it generates. This is possible because the company has used debt to leverage its assets. Without this debt the RoE would be a more moderate 16%.

By historical measures the cost of borrowing has been extremely low for a number of years now. This has enabled companies like CSL to use debt to fund some of their growth. One benefit that CSL has over other companies is that its products are less cyclical and it has strong cash flows. This enables the company to service its interest payments.

For FY19 CSL is targeting the upper end of its full year profit guidance. This would represent 13% year on year growth to between US$1,880 million and US$1,950 million. Shares currently trade around 32x estimated forward earnings and offer an unfranked dividend yield of 1%.

Foolish bottom line

Although CSL trades on a rich valuation compared to its current earnings growth, the strong track record and long term prospects of the company are sound. I'd like to buy shares cheaper than they are today, however it is important to note that high quality companies like CSL generally trade at a premium.

If you like the sound of CSL, here are some other high quality growth companies.

Lloyd Prout has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Magnifying glass on a rising interest rate graph.
Share Market News

Will the RBA finally cut interest rates next week?

Let's see what economists are saying about the central bank's meeting.

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors endured a rough Friday to close the trading week today.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Broker Notes

7 ASX All Ords shares elevated to 'strong buy' status in October

The brokers turned bullish on these ASX companies last month.

Read more »

A businessman compares the growth trajectory of property versus shares.
Share Market News

How ASX shares vs. property performed in October

The national home value rose for the 21st consecutive month while the ASX 200 dipped.

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

The worst 3 ASX 200 stocks to buy and hold in October unmasked

You would have done well to avoid these three ASX 200 stocks in October.

Read more »

A female Woolworths customer leans on her shopping trolley as she rests her chin in her hand thinking about what to buy for dinner while also wondering why the Woolworths share price isn't doing as well as Coles recently
52-Week Lows

Why is the Woolworths share price at its lowest point since 2020?

We haven't seen Woolies shares this low since COVID.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why AFT, Amcor, Corporate Travel, and Macquarie shares are falling today

These shares are ending the week in the red. But why?

Read more »